tbuckley/cabot-search huggingface dataset:
Invasive Treatment Strategy for Older Patients with Myocardial Infarction
Authors: Vijay Kunadian, Helen Mossop, Carol Shields, Michelle Bardgett, Philippa Watts, M Dawn Teare, Jonathan Pritchard, Jennifer Adams-Hall, Craig Runnett, David P Ripley, Justin Carter, Julie Quigley, Justin Cooke, David Austin, Jerry Murphy, Damian Kelly, James McGowan, Murugapathy Veerasamy, Dirk Felmeden, Hussain Contractor, Sanjay Mutgi, John Irving, Steven Lindsay, Gavin Galasko, Kelvin Lee, Ayyaz Sultan, Amardeep G Dastidar, Shazia Hussain, Iftikhar Ul Haq, Mark de Belder, Martin Denvir, Marcus Flather, Robert F Storey, David E Newby, Stuart J Pocock, Keith A A Fox
Journal: New England Journal of Medicine (2024)

BackgroundWhether a conservative strategy of medical therapy alone or a strategy of medical therapy plus invasive treatment is more beneficial in older adults with non–ST-segment elevation myocardial infarction (NSTEMI) remains unclear.MethodsWe conducted a prospective, multicenter, randomized trial involving patients 75 years of age or older with NSTEMI at 48 sites in the United Kingdom. The patients were assigned in a 1:1 ratio to a conservative strategy of the best available medical therapy or an invasive strategy of coronary angiography and revascularization plus the best available medical therapy. Patients who were frail or had a high burden of coexisting conditions were eligible. The primary outcome was a composite of death from cardiovascular causes (cardiovascular death) or nonfatal myocardial infarction assessed in a time-to-event analysis.ResultsA total of 1518 patients underwent randomization; 753 patients were assigned to the invasive-strategy group and 765 to the conservative-strategy group. The mean age of the patients was 82 years, 45% were women, and 32% were frail. A primary-outcome event occurred in 193 patients (25.6%) in the invasive-strategy group and 201 patients (26.3%) in the conservative-strategy group (hazard ratio, 0.94; 95% confidence interval [CI], 0.77 to 1.14; P=0.53) over a median follow-up of 4.1 years. Cardiovascular death occurred in 15.8% of the patients in the invasive-strategy group and 14.2% of the patients in the conservative-strategy group (hazard ratio, 1.11; 95% CI, 0.86 to 1.44). Nonfatal myocardial infarction occurred in 11.7% in the invasive-strategy group and 15.0% in the conservative-strategy group (hazard ratio, 0.75; 95% CI, 0.57 to 0.99). Procedural complications occurred in less than 1% of the patients.ConclusionsIn older adults with NSTEMI, an invasive strategy did not result in a significantly lower risk of cardiovascular death or nonfatal myocardial infarction (the composite primary outcome) than a conservative strategy over a median follow-up of 4.1 years. (Funded by the British Heart Foundation; BHF SENIOR-RITA ISRCTN Registry number, ISRCTN11343602.)
51252 Oral supplementation with L-Cystine, Serenoa repens, Pumpkin seed oil and Pygeum africanum in Chronic Telogen Effluvium and Androgenetic Alopecia: A double-blind, placebo-controlled, randomized clinical study
Authors: Jaime Piquero-Casals, David Saceda-Corralo, Sonia Aladren, Javier Bustos, Albert Navasa, Georgina Logusso, Eric Jourdan, Juan Francisco Mir-Bonafé
Journal: Journal of the American Academy of Dermatology (2024)
Complete vs. Culprit-Only Revascularization in Older Patients with ST-segment Elevation Myocardial Infarction: An Individual Patient Meta-Analysis
Authors: Gianluca Campo, Feix Böhm, Thomas Engstrøm, Pieter C. Smits, Islam Y. Elgendy, Gerry McCann, David Wood, Matteo Serenelli, Stefan James, Dan Eik Høfsten, Bianca Boxma-de Klerk, Adrian Banning, John A. Cairns, Rita Pavasini, Goran Stankovic, Petr Kala, Henning Kelbæk, Emanuele Barbato, Ilija Srdanovic, Mohamed Hamza, Amerjeet S. Banning, Simone Biscaglia, Shamir Mehta
Journal: Circulation (2024)

Background: Complete revascularization is the standard treatment for patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease. The Functional Assessment in Elderly MI Patients with Multivessel Disease (FIRE) trial confirmed the benefit of complete revascularization in a population of older patients, but the follow-up is limited to 1 year. Therefore, the long-term benefit ( &gt; 1-year) of this strategy in older patients is debated. To address this, an individual patient data meta-analysis was conducted in STEMI patients aged 75 years or older enrolled in randomized clinical trials investigating complete vs. culprit-only revascularization strategies. Methods: PubMed, Embase, and the Cochrane database, were systematically searched to identify randomized clinical trials comparing complete vs. culprit-only revascularization. Individual patient-level data were collected from the relevant trials. The primary endpoint was death, myocardial infarction (MI), or ischemia-driven revascularization. The secondary endpoint was cardiovascular death or myocardial infarction. Results: Data from seven RCTs, encompassing 1733 patients (917 randomized to culprit-only and 816 to complete revascularization), were analyzed. The median age was 79 [77-83] years. Females were 595 (34%). Follow-up ranged from a minimum of six months to a maximum of 6.2 years (median 2.5 [1-3.8] years). Complete revascularization reduced the primary endpoint up to four years (HR 0.78, 95%CI 0.63-0.96), but not at the longest available follow-up (HR 0.83, 95%CI 0.69-1.01). Complete revascularization significantly reduced the occurrence of cardiovascular death or MI at the longest available follow-up (HR 0.76, 95%CI 0.58-0.99). This was observed even when censoring the follow-up at each year. Long-term rate of death did not differ between complete and culprit-only revascularization arms. Conclusions: In this individual patient data meta-analysis of older STEMI patients with multivessel disease, complete revascularization reduced the primary endpoint of death, MI or ischemia-driven revascularization up to 4-year. At the longest follow-up, complete revascularization reduced the composite of cardiovascular death or MI, but not the primary endpoint. Clinical Study Registration: PROSPERO CRD42022367898
49140 Clinical similarity of SB17 (Proposed Ustekinumab Biosimilar) to Reference Ustekinumab in Patients with Moderate to Severe Plaque Psoriasis: Randomized, Double-blind, Phase III, 52-Week Results
Authors: Steven Feldman, Joanna Narbutt, Giampiero Girolomoni, Jan Brzezicki, Nataliya Reznichenko, Grazyna Pulka, Magdalena Dmowska-Stecewicz, Jiyoon Lee, Minkyung Lee, Young Hee Rho
Journal: Journal of the American Academy of Dermatology (2024)
52687 Bimekizumab improvement in three Dermatology Life Quality Index (DLQI) items capturing aspects most burdensome to patients with moderate to severe plaque psoriasis
Authors: Matthias Augustin, Jennifer Cather, Kim A. Papp, Michael Sebastian, Satoru Arai, Rhys Warham, Bengt Hoepken, Jérémy Lambert, Balint Szilagyi, April Armstrong
Journal: Journal of the American Academy of Dermatology (2024)
50170 Cross-Sectional Survey of Hands-on Cosmetic and Laser Training in Dermatology Residency
Authors: Bianca Kang, Kira Minkis, Kathleen Suozzi, Tanya Greywal, Elika Hoss, Diana Bolotin, Nour Kibbi, Murad Alam
Journal: Journal of the American Academy of Dermatology (2024)
Sacubitril/valsartan reduces incident anaemia and iron therapy utilization in heart failure: The <scp>PARAGON</scp>‐<scp>HF</scp> trial
Authors: Henri Lu, Brian L. Claggett, Milton Packer, Marc A. Pfeffer, Carolyn S.P. Lam, Michael R. Zile, Akshay S. Desai, Pardeep Jhund, Martin Lefkowitz, John J.V. McMurray, Scott D. Solomon, Muthiah Vaduganathan
Journal: European Journal of Heart Failure (2024)
Immunosuppressant therapy averts rejection of allogeneic FKBP1A-disrupted CAR-T cells
Authors: Colby R. Maldini, Angelica C. Messana, Paula B. Bendet, Adam J. Camblin, Faith M. Musenge, Moriah L. White, Joseph J. Rocha, Lindsey J. Coholan, Cisem Karaca, Frederick Li, Bo Yan, Vladimir D. Vrbanac, Emily Marte, Daniel T. Claiborne, Christian L. Boutwell, Todd M. Allen
Journal: Molecular Therapy (2024)

Chimeric antigen receptor (CAR) T cells from allogeneic donors promise "off-the-shelf" availability by overcoming challenges associated with autologous cell manufacturing. However, recipient immunologic rejection of allogeneic CAR-T cells may decrease their in vivo lifespan and limit treatment efficacy. Here, we demonstrate that the immunosuppressants rapamycin and tacrolimus effectively mitigate allorejection of HLA-mismatched CAR-T cells in immunocompetent humanized mice, extending their in vivo persistence to that of syngeneic humanized mouse-derived CAR-T cells. In turn, genetic knockout (KO) of FKBP prolyl isomerase 1A (FKBP1A), which encodes a protein targeted by both drugs, was necessary to confer CD19-specific CAR-T cells (19CAR) robust functional resistance to these immunosuppressants. FKBP1A
Asundexian versus Apixaban in Patients with Atrial Fibrillation
Authors: Jonathan P Piccini, Manesh R Patel, Jan Steffel, Keith Ferdinand, Isabelle C Van Gelder, Andrea M Russo, Chang-Sheng Ma, Shaun G Goodman, Jonas Oldgren, Christopher Hammett, Renato D Lopes, Masaharu Akao, Raffaele De Caterina, Paulus Kirchhof, Diana A Gorog, Martin Hemels, Michiel Rienstra, W Schuyler Jones, Josephine Harrington, Gregory Y H Lip, Stephen J Ellis, Frank W Rockhold, Christoph Neumann, John H Alexander, Thomas Viethen, James Hung, Rosa Coppolecchia, Hardi Mundl, Valeria Caso
Journal: New England Journal of Medicine (2024)

BackgroundStroke prevention with direct-acting oral anticoagulant agents in patients with atrial fibrillation confers a risk of bleeding and limits their use. Asundexian, an activated factor XI (XIa) inhibitor, is an oral anticoagulant that may prevent strokes with less bleeding.MethodsIn a phase 3, international, double-blind trial, we randomly assigned high-risk patients with atrial fibrillation in a 1:1 ratio to receive asundexian at a dose of 50 mg once daily or standard-dose apixaban. The primary efficacy objective was to determine whether asundexian is at least noninferior to apixaban for the prevention of stroke or systemic embolism. The primary safety objective was to determine whether asundexian is superior to apixaban with respect to major bleeding events.ResultsA total of 14,810 randomly assigned patients were included in the intention-to-treat population. The mean (±SD) age of the patients was 73.9±7.7 years, 35.2% were women, 18.6% had chronic kidney disease, 18.2% had a previous stroke or transient ischemic attack, 16.8% had received oral anticoagulants for no more than 6 weeks, and the mean CHA2DS2-VASc score (range, 0 to 9, with higher scores indicating a greater risk of stroke) was 4.3±1.3. The trial was stopped prematurely at the recommendation of the independent data monitoring committee. Stroke or systemic embolism occurred in 98 patients (1.3%) assigned to receive asundexian and in 26 (0.4%) assigned to receive apixaban (hazard ratio, 3.79; 95% confidence interval [CI], 2.46 to 5.83). Major bleeding occurred in 17 patients (0.2%) who received asundexian and in 53 (0.7%) who received apixaban (hazard ratio, 0.32; 95% CI, 0.18 to 0.55). The incidence of any adverse event appeared to be similar in the two groups.ConclusionsAmong patients with atrial fibrillation at risk for stroke, treatment with asundexian at a dose of 50 mg once daily was associated with a higher incidence of stroke or systemic embolism than treatment with apixaban in the period before the trial was stopped prematurely. There were fewer major bleeding events with asundexian than with apixaban during this time. (Funded by Bayer; OCEANIC-AF ClinicalTrials.gov number, NCT05643573; EudraCT number, 2022-000758-28.)
Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy
Authors: Charles F. Sherrod, Sara Saberi, Michael E. Nassif, Brian L. Claggett, Caroline J. Coats, Pablo Garcia-Pavia, James L. Januzzi, Gregory D. Lewis, Changsheng Ma, Martin S. Maron, Zi Michael Miao, Iacopo Olivotto, Josef Veselka, Michael Butzner, Daniel L. Jacoby, Stephen B. Heitner, Stuart Kupfer, Fady I. Malik, Lisa Meng, Amy Wohltman, John A. Spertus
Journal: Journal of the American College of Cardiology (2024)

A primary goal in treating obstructive hypertrophic cardiomyopathy (oHCM) is to improve patients' health status: their symptoms, function, and quality of life. The health status benefits of aficamten, a novel cardiac myosin inhibitor, have not been comprehensively described. This study sought to determine the effect of aficamten on patient-reported health status, including symptoms of fatigue, shortness of breath, chest pain, physical and social limitations, and quality of life. SEQUOIA-HCM (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM) randomized symptomatic adults with oHCM to 24 weeks of aficamten (n = 142) or placebo (n = 140), followed by a 4-week washout. The Kansas City Cardiomyopathy Questionnaire (KCCQ) and Seattle Angina Questionnaire 7-item (SAQ7) were serially administered. Changes in mean KCCQ—Overall Summary Score (KCCQ-OSS) and SAQ7—Summary Score (SAQ7-SS) from baseline to 24 weeks and following treatment withdrawal were compared using linear regression adjusted for baseline scores and randomization strata. Proportions of patients with clinically important changes were compared. Among 282 participants, the mean age was 59 ± 13 years, 115 (41%) were female, and 223 (79%) were White. Baseline KCCQ-OSS (69.3 ± 20.1 vs 67.3 ± 18.8) and SAQ7-SS (72.0 ± 21.0 vs 72.4 ± 18.3) were similar between aficamten and placebo groups. Treatment with aficamten, compared with placebo, improved both the mean KCCQ-OSS (13.3 ± 16.3 vs 6.1 ± 12.6; mean difference: 7.9; 95% CI: 4.8-11.0; P < 0.001) and SAQ7-SS (11.6 ± 17.4 vs 3.8 ± 14.4; mean difference: 7.8; 95% CI: 4.7-11.0; P < 0.001) at 24 weeks, with benefits emerging within 4 weeks. No heterogeneity in treatment effect was found across subgroups. A much larger proportion of participants experienced a very large health status improvement (≥20 points) with aficamten vs placebo (KCCQ-OSS: 29.7% vs 12.4%, number needed to treat: 5.8; SAQ7-SS: 31.2% vs 13.9%, number needed to treat: 5.8). Participants' health status worsened significantly more after withdrawal from aficamten than placebo (KCCQ-OSS: −16.2 ± 19.0 vs −3.0 ± 9.6; P < 0.001; SAQ7-SS: −17.4 ± 21.4 vs −2.5 ± 13.3), further confirming a causal effect of aficamten. In patients with symptomatic oHCM, treatment with aficamten resulted in markedly improved health status, including significant improvement in chest pain-related health status, than placebo. (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM [SEQUOIA-HCM]; NCT05186818)
Temporal Trends in Takotsubo Syndrome
Authors: Victor Schweiger, Victoria L. Cammann, Giulia Crisci, Thomas Gilhofer, Rabea Schlenker, David Niederseer, Shaojie Chen, Ramin Ebrahimi, Florian Wenzl, Michael Würdinger, Rodolfo Citro, Carmine Vecchione, Sebastiano Gili, Michael Neuhaus, Jennifer Franke, Benjamin Meder, Miłosz Jaguszewski, Michel Noutsias, Maike Knorr, Thomas Jansen, Fabrizio D’Ascenzo, Wolfgang Dichtl, Dirk von Lewinski, Christof Burgdorf, Behrouz Kherad, Carsten Tschöpe, Annahita Sarcon, Jerold Shinbane, Lawrence Rajan, Guido Michels, Roman Pfister, Alessandro Cuneo, Claudius Jacobshagen, Mahir Karakas, Wolfgang Koenig, Alexander Pott, Philippe Meyer, Marco Roffi, Adrian Banning, Mathias Wolfrum, Florim Cuculi, Richard Kobza, Thomas A. Fischer, Tuija Vasankari, K.E. Juhani Airaksinen, L. Christian Napp, Rafal Dworakowski, Philip MacCarthy, Christoph Kaiser, Stefan Osswald, Leonarda Galiuto, Christina Chan, Paul Bridgman, Daniel Beug, Clément Delmas, Olivier Lairez, Ekaterina Gilyarova, Alexandra Shilova, Mikhail Gilyarov, Ibrahim El-Battrawy, Ibrahim Akin, Karolina Poledniková, Petr Toušek, David E. Winchester, Michael Massoomi, Jan Galuszka, Christian Ukena, Gregor Poglajen, Pedro Carrilho-Ferreira, Christian Hauck, Carla Paolini, Claudio Bilato, Yoshio Kobayashi, Ken Kato, Iwao Ishibashi, Toshiharu Himi, Jehangir Din, Ali Al-Shammari, Abhiram Prasad, Charanjit S. Rihal, Kan Liu, P. Christian Schulze, Matteo Bianco, Lucas Jörg, Hans Rickli, Gonçalo Pestana, Thanh H. Nguyen, Michael Böhm, Lars S. Maier, Fausto J. Pinto, Petr Widimský, Stephan B. Felix, Ruediger C. Braun-Dullaeus, Wolfgang Rottbauer, Gerd Hasenfuß, Burkert M. Pieske, Heribert Schunkert, Monika Budnik, Grzegorz Opolski, Holger Thiele, Johann Bauersachs, John D. Horowitz, Carlo Di Mario, William Kong, Mayank Dalakoti, Yoichi Imori, Thomas Münzel, Luca Liberale, Fabrizio Montecucco, Jeroen J. Bax, Filippo Crea, Frank Ruschitzka, Thomas F. Lüscher, Jelena R. Ghadri, Eduardo Bossone, Christian Templin, Davide Di Vece
Journal: Journal of the American College of Cardiology (2024)
54772 Pigmentary disorders, prevalence, impact on quality of life and social stigmatization: Results of the first large international survey
Authors: Delphine Kerob Kerob, Thierry Passeron, Andrew Alexis, Brigitte Dreno, Liu Wei, Akimichi Akimichi Morita, Chee Leok, Susana Puig, Sergio Schalka, Henry W. Lim
Journal: Journal of the American Academy of Dermatology (2024)
53982 Measurement of musculoskeletal symptoms in patients with hidradenitis suppurativa: preliminary evaluation of the IDEOM MSK-Q’s content validity
Authors: Lourdes Perez-Chada, Arianna Zhang, Gretchen Ball, Michael Woodbury, Melissa Zundell, April Armstrong, Vibeke Strand, Joseph F. Merola, Alice B. Gottlieb
Journal: Journal of the American Academy of Dermatology (2024)
54225 Elevated circulating blood eosinophils and inflammatory laboratory markers as predictors of incident diabetes mellitus in patients with atopic dermatitis: a multicenter cohort study
Authors: Brenda Umenita Imo, Jaya Manjunath, Alexander Kollhoff, Emily Ma, Selina Yossef, Weiying Lu, Shawn Kwatra
Journal: Journal of the American Academy of Dermatology (2024)
53902 Can a cleansing gel remove sebum without stripping the skin? Evaluation of a salicylic acid and ceramide-containing cleanser
Authors: Camila Valpaços Gomes, Priscila Correia, Mariana Feiges, Nada Baalbaki, Diego Svoboda, Alessandro Nascimento, Erika Fernandes
Journal: Journal of the American Academy of Dermatology (2024)
52306 Clinical Assessment of Anti-Aging Benefits of a Facial Skincare Formulation: a biomarker-centered approach to antioxidative defense
Authors: Ana Lucia Tabarini Alves Pinheiro, Silas Arandas Monteiro Silva, Leticia Gomes, Carla Monserrat Grecco Lopes, Barbara de Freitas Carli, Vania Renata Gonçalves, Gustavo Facchini, Samara Eberlin
Journal: Journal of the American Academy of Dermatology (2024)
Atrial Fibrillation and Stable Coronary Artery Disease
Authors: Gregory Y H Lip
Journal: New England Journal of Medicine (2024)

Patients with atrial fibrillation are at high risk for stroke, and international guidelines recommend oral anticoagulant therapy. In patients with stable vascular disease without atrial fibrillation, antiplatelet therapy is recommended. However, atrial fibrillation commonly coexists with vascular diseases, such as coronary artery disease. When patients with both conditions present with an acute coronary syndrome or need to undergo percutaneous coronary intervention for implantation of a stent, management with oral anticoagulant therapy plus antiplatelet therapy is clearly supported by evidence from randomized trials. However, the evidence base is less clear for patients with atrial fibrillation and stable vascular disease. The clinician . . .
Insights into microscopic fabrication, macroscopic forms and biomedical applications of alginate composite gel containing metal-organic frameworks
Authors: Yuanke Zhang, Lvyao Yang, Min Zhou, Yanhua Mou, Dongmei Wang, Peng Zhang
Journal: Asian Journal of Pharmaceutical Sciences (2024)

Overcoming the poor physicochemical properties of pure alginate gel and the inherent shortcomings of pure metal organic framework (MOF), alginate/ MOF composite gel has captured the interest of many researchers as a tunable platform with high stability, controllable pore structure, and enhanced biological activity. Interestingly, different from the traditional organic or inorganic nanofillers physically trapped or chemically linked within neTtworks, MOFs crystals can not only be dispersed by crosslinking polymerization, but also support self-assembly in-situ under the help of chelating cations with alginate. The latter is influenced by multiple factors and may involve some complex mechanisms of action, which is also a topic discussed deeply in this article while summarizing different preparation routes. Furthermore, various physical and chemical levels of improvement strategies and available macroforms are summarized oriented towards obtaining composite gel with ideal performance. Finally, the application status of this composite system in drug delivery, wound healing and other biomedical fields is further discussed. And the current limitations and future development directions are shed light simultaneously, which may provide guidance for the vigorous development of these composite systems.
Unlocking the role of wound microbiome in diabetic, burn, and germ-free wound repair treated by natural and synthetic scaffolds
Authors: Zeyu Xu, Lixiang Zhang, Qinghan Tang, Chenxi Yang, Xiaotong Ding, Ziyu Wang, Rizhong Huang, Ruihan Jiang, Joannake Maitz, Huaikai Shi, Xin Yan, Mei Dong, Jun Chen, Yiwei Wang
Journal: Acta Pharmaceutica Sinica B (2024)

In current clinical practice, various dermal templates and skin substitutes are used to enhance wound healing. However, the role of wound commensal microbiome in regulating scaffold performance and the healing process remains unclear. In this study, we investigated the influence of both natural and synthetic scaffolds on the wound commensal microbiome and wound repair in three distinct models including diabetic wounds, burn injuries, and germ-free (GF) wounds. Remarkably, synthetic electrospun polycaprolactone (PCL) scaffolds were observed to positively promote microbiome diversity, leading to enhanced diabetic wound healing compared to the natural scaffolds Integra® (INT) and MatriDerm® (MAD). In contrast, both natural and synthetic scaffolds exhibited comparable effects on the diversity of the microbiome and the healing of burn injuries. In GF wounds with no detectable microorganisms, a reversed healing rate was noted showing natural scaffold (MAD) accelerated wound repair compared to the open or the synthetic scaffold (PCL) treatment. Furthermore, the response of the wound commensal microbiome to PCL scaffolds appears pivotal in promoting anti-inflammatory factors during diabetic wound healing. Our results emphasize that the wound commensal microbiome, mediated by different scaffolds plays an important role in the wound healing process.
Expert consensus on the diagnosis and therapy of endo-periodontal lesions
Authors: Bin Chen, Yanan Zhu, Minkui Lin, Yangheng Zhang, Yanfen Li, Xiangying Ouyang, Song Ge, Jiang Lin, Yaping Pan, Yan Xu, Yi Ding, Shaohua Ge, Faming Chen, Zhongchen Song, Shaoyun Jiang, Jiang Sun, Lijun Luo, Junqi Ling, Zhi Chen, Lin Yue, Xuedong Zhou, Fuhua Yan
Journal: International Journal of Oral Science (2024)

Abstract Endo-periodontal lesions (EPLs) involve both the periodontium and pulp tissue and have complicated etiologies and pathogenic mechanisms, including unique anatomical and microbiological characteristics and multiple contributing factors. This etiological complexity leads to difficulties in determining patient prognosis, posing great challenges in clinical practice. Furthermore, EPL-affected teeth require multidisciplinary therapy, including periodontal therapy, endodontic therapy and others, but there is still much debate about the appropriate timing of periodontal therapy and root canal therapy. By compiling the most recent findings on the etiology, pathogenesis, clinical characteristics, diagnosis, therapy, and prognosis of EPL-affected teeth, this consensus sought to support clinicians in making the best possible treatment decisions based on both biological and clinical evidence.